Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy
Authors
Keywords
-
Journal
Cancer Nanotechnology
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-03-28
DOI
10.1186/s12645-023-00177-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo
- (2022) Yacong An et al. MOLECULES
- Cancer immunomodulation using bispecific aptamers
- (2022) Brian J. Thomas et al. Molecular Therapy-Nucleic Acids
- Insights into the binding mode of AS1411 aptamer to nucleolin
- (2022) Lihua Bie et al. Frontiers in Molecular Biosciences
- Novel Complex of PD-L1 Aptamer and Holliday Junction Enhances Antitumor Efficacy in Vivo
- (2021) Ting Li et al. MOLECULES
- Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy
- (2021) G. Fucà et al. ESMO Open
- Targeted Therapy of Colon Cancer by Aptamer-Guided Holliday Junctions Loaded with Doxorubicin
- (2020) Fengjiao Yao et al. International Journal of Nanomedicine
- The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
- (2020) Florent Petitprez et al. Frontiers in Immunology
- Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel
- (2020) Zhen Yu et al. International Journal of Nanomedicine
- PD-1+ Treg cells: a foe in cancer immunotherapy?
- (2020) Halil-Ibrahim Aksoylar et al. NATURE IMMUNOLOGY
- Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
- (2020) Sreya Bagchi et al. Annual Review of Pathology-Mechanisms of Disease
- Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting
- (2019) Zhaoyi Li et al. MOLECULES
- An exploration of aptamer internalization mechanisms and their applications in drug delivery
- (2019) Lin-Yan Wan et al. Expert Opinion on Drug Delivery
- A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
- (2019) Frans V. Suurs et al. PHARMACOLOGY & THERAPEUTICS
- Aptamer-based Targeted Delivery of a G-quadruplex Ligand in Cervical Cancer Cells
- (2019) Josué Carvalho et al. Scientific Reports
- Therapeutic applications of AS1411 aptamer, an update review
- (2019) Rezvan Yazdian-Robati et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
- (2018) Caroline Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Aptamer Therapeutics in Cancer: Current and Future
- (2018) Yoshihiro Morita et al. Cancers
- Aptamer-based targeted therapy
- (2018) Guizhi Zhu et al. ADVANCED DRUG DELIVERY REVIEWS
- A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect
- (2017) Bo-Tsang Huang et al. Molecular Therapy-Nucleic Acids
- MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells
- (2016) Mario Martínez Soldevilla et al. Oncotarget
- A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects
- (2016) Wei-Yun Lai et al. Molecular Therapy-Nucleic Acids
- Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia
- (2015) Nianxi Zhao et al. BIOMATERIALS
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Sub-10-nm Pd Nanosheets with Renal Clearance for Efficient Near-Infrared Photothermal Cancer Therapy
- (2014) Shaoheng Tang et al. Small
- Bi-specific Aptamers Mediating Tumor Cell Lysis
- (2011) Achim Boltz et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting 4-1BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers
- (2011) Fernando Pastor et al. MOLECULAR THERAPY
- Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
- (2009) Paula J. Bates et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- The Nucleolin Targeting Aptamer AS1411 Destabilizes Bcl-2 Messenger RNA in Human Breast Cancer Cells
- (2008) S. Soundararajan et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started